8-K: Leap Therapeutics Announces Positive Clinical Trial Results and Year-End Financials

Leap Therapeutics reported promising clinical data for its DKN-01 drug in cancer trials and its year-end 2023 financial results.

Summary

• Leap Therapeutics announced its financial results for the fourth quarter and year ended December 31, 2023.
• The company presented positive initial data from Part A of the DeFianCe study, showing a 30% overall response rate and a 93% disease control rate in second-line colorectal cancer patients using DKN-01 in combination with standard treatments.
• The study also showed enhanced activity in patients with left-sided tumors, with a 33% overall response rate and 100% disease control rate.
• Patients with rectal/rectosigmoid carcinomas showed a 46% overall response rate and 100% disease control rate.
• Enrollment has been completed in Part C of the DisTinGuish study, with initial data expected in mid-2024.
• The company reported a net loss of $81.4 million for the year ended December 31, 2023, compared to a $54.6 million loss in 2022.
• Research and development expenses increased to $73.2 million for the full year 2023, up from $45.0 million in 2022.
• General and administrative expenses were $13.8 million for the full year 2023, compared to $11.8 million in 2022.
• Cash and cash equivalents totaled $70.6 million at December 31, 2023.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial results, which are a significant positive. However, the increased net loss and expenses are a concern, leading to a moderately positive sentiment.

Positives

• The DeFianCe study demonstrated strong clinical results for DKN-01 in colorectal cancer, particularly in specific patient subgroups.
• The completion of enrollment in the DisTinGuish study positions the company to deliver important data in mid-2024.
• DKN-01 was well-tolerated in the DeFianCe study, with most related events being low grade.
• Higher baseline plasma DKK1 levels correlated with improved responses in the DeFianCe study.

Negatives

• The company experienced a significant increase in net loss, from $54.6 million in 2022 to $81.4 million in 2023.
• Research and development expenses increased substantially, from $45.0 million in 2022 to $73.2 million in 2023.
• General and administrative expenses also increased, from $11.8 million in 2022 to $13.8 million in 2023.

Risks

• The company's ability to successfully execute its clinical trials and the timing of enrollment are subject to risks.
• The results of clinical trials and pre-clinical studies may not be as expected.
• The company's ability to enter into new strategic partnerships and maintain existing collaborations is not guaranteed.
• There is a risk that clinical trials and products may not receive regulatory approval.
• The company is exposed to inflation, currency rate, and interest rate fluctuations.
• Global conflicts and supply chain issues could delay or adversely affect operations.

Future Outlook

The company anticipates completing enrollment in Part B of the DeFianCe study in mid-2024 and reporting initial data from Part C of the DisTinGuish study in mid-2024.

Management Comments

• Douglas E. Onsi, President and Chief Executive Officer of Leap, stated that the data from Part A of the DeFianCe study showcases a strong foundation as they move into the randomized controlled Part B of the study.
• Mr. Onsi also mentioned that the completion of enrollment in Part C of the DisTinGuish study positions them to deliver the first randomized controlled data for DKN-01 starting in the middle of the year.

Industry Context

The announcement is relevant to the biotechnology industry, particularly companies focused on developing targeted and immuno-oncology therapeutics. The positive clinical data for DKN-01 could position Leap as a potential player in the cancer treatment space. The increased R&D spending is typical for companies in this sector as they advance clinical trials.

Comparison to Industry Standards

• The 30% overall response rate in the DeFianCe study is promising compared to standard second-line colorectal cancer treatments, which often have lower response rates.
• The 93% disease control rate is also notable, indicating that the treatment is effective in stabilizing the disease in a large proportion of patients.
• Companies like Regeneron and Bristol Myers Squibb have similar programs in immuno-oncology, but the specific DKK1 target of DKN-01 is a differentiator.
• The median PFS of 6.3 months is a key metric that will be compared to other treatments in the same space, such as those using bevacizumab and chemotherapy alone.
• The increase in R&D spending is consistent with other biotech companies in clinical development, but the net loss is a concern that will need to be addressed.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Employees may be encouraged by the progress of the company's drug development programs.
• Patients with cancer may benefit from the development of new treatment options.
• The company's financial performance may impact its ability to secure future funding and partnerships.

Next Steps

• The company expects to complete enrollment in Part B of the DeFianCe study in mid-2024.
• The company expects to report initial data from Part C of the DisTinGuish study in mid-2024.

Key Dates

Keywords

DKN-01, colorectal cancer, gastroesophageal cancer, clinical trial, oncology, biotechnology, research and development, financial results, immunotherapy, targeted therapy